Beyond The BLA: Off-Label, Shortage Issues Influence Telesta MCNA Review
Executive Summary
FDA advisory committee wonders if approving Telesta's MCNA might lead bladder cancer patients to get treatment that is less effective than off-label chemo; panelists also debate whether MCNA could or should play role in alleviating drug shortages.